Core Viewpoint - Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. shareholders regarding potential breaches of fiduciary duties by certain officers of the company [1] Investigation Basis - A securities fraud class action complaint alleges that Inspire Medical misled investors about the launch of its key product, the Inspire V sleep apnea device, claiming it met all necessary conditions for a successful launch, while in reality, the launch faced significant issues [3] - The complaint states that demand for Inspire V was low due to customers having excess inventory of older devices, and that the company failed to ensure proper uptake by clinicians and payors, leading to delays in adoption [3] - Following the revelation of these issues on August 4, 2025, Inspire Medical's stock price dropped by 32%, resulting in a loss of over $1.5 billion in shareholder value [3] Actions for Shareholders - Current shareholders who have held Inspire Medical shares since before August 6, 2024, can pursue corporate reforms, seek the return of funds to the company, and obtain a court-approved incentive award at no cost [2][4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific claims include that Baxter was aware of multiple device malfunctions and that its remedial measures were inadequate, resulting in a heightened risk of product recalls and sales pauses [5] - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, causing investor damages when the truth was revealed [5]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud due to significant stock drops linked to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case in the U.S. District Court for the Southern District of New York [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [4]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and posing health risks to customers [5]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to revelations about product quality issues, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [6]. - After the FDA published details of unauthorized modifications on March 25, 2025, the stock fell another $3.19 per share (over 4%) [7]. - A report by Hunterbrook on September 18 revealed severe issues, leading to a nearly 12% drop of $8.99 per share over two trading days [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter in response to reported malfunctions and injuries [5]. - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Inspire Medical Systems, Inc. for allegedly misleading investors about its business operations and the market demand for its sleep apnea device, Inspire V [1][2][3]. Summary by Sections Allegations - The lawsuit claims that during the class period from August 6, 2024, to August 4, 2025, Inspire Medical misrepresented key facts about the Inspire V device, including its actual market demand and the steps taken for its launch [3]. Class Action Participation - Shareholders who wish to serve as lead plaintiffs must file motions by January 5, 2026. Participation in the case is not required to be eligible for recovery [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for allegedly misleading investors regarding the demand and launch of its implantable medical device for obstructive sleep apnea during the specified class period [1][3]. Summary by Sections Lawsuit Details - The lawsuit claims that during the class period from August 6, 2024, to August 4, 2025, Inspire Medical made false statements and failed to disclose poor demand for its product, leading to significant inventory issues and reluctance from providers to adopt the new treatment [3]. - The company allegedly assured investors that all necessary steps for a successful product launch were taken, which was later contradicted by the company's own admissions regarding incomplete training and onboarding at treatment centers [3]. Company Performance - On August 4, 2025, Inspire Medical disclosed that the launch of Inspire V was delayed due to many centers not completing required training and contracting, which affected the ability to bill for procedures [4]. - The company also revealed that the rollout faced poor demand due to excess inventory, resulting in a more than 80% reduction in its 2025 earnings guidance [4]. - Following this announcement, Inspire's share price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 [4]. Investor Actions - Investors who suffered losses during the class period have until January 5, 2025, to request lead plaintiff appointment in the class action lawsuit [1]. - The lead plaintiff appointment process allows investors with the largest financial losses to represent the class, influencing case strategy and settlement decisions [6].

Core Viewpoint - Globus Medical's acquisition of Nevro has positively impacted its financial performance, leading to a significant increase in stock value and an optimistic outlook for future earnings growth [2][3][4]. Financial Performance - Globus Medical reported third-quarter sales of $769 million, representing a 6.4% organic growth, surpassing forecasts of $735 million [4]. - Adjusted earnings per share reached $1.18, exceeding expectations of 78 cents, with a notable 42% increase year-over-year [4]. - Nevro's sales were $99 million, reflecting a modest 2% year-over-year growth, but its adjusted EBITDA margin improved to 16% from a prior loss of 1% [2][4]. Future Outlook - The company has raised its full-year sales guidance to a range of $2.86 billion to $2.9 billion, up from the previous range of $2.8 billion to $2.9 billion [6]. - Adjusted profit expectations have also increased to $3.75 to $3.85 per share, marking a 65-cent increase at the midpoint from previous guidance [6]. - Management anticipates that the Nevro division will become accretive by 2025, earlier than previously expected [3]. Market Reaction - Following the positive earnings report, Globus Medical's stock surged by 36.1%, closing at $83.89, marking an eight-month high and surpassing its 200-day moving average [3][4].

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud related to the company's glucose monitoring products, specifically the G6 and G7 models, which are claimed to have undergone unauthorized design changes that compromised their reliability and safety [1][2]. Group 1: Allegations and Impact - The lawsuit claims that DexCom made material design changes to the G6 and G7 glucose monitoring products without FDA authorization [2]. - These design changes allegedly rendered the devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [2]. - The enhancements claimed by the defendants regarding the G7's reliability, accuracy, and functionality were reportedly overstated [2]. - The lawsuit suggests that the company downplayed the severity of the issues and health risks associated with the altered G7 devices [2]. - As a result of these actions, DexCom is said to face increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by the defendants are characterized as materially false and misleading throughout the relevant time period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require individuals to serve as lead plaintiffs, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Share Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK--(BUSINESS WIRE)--Faruq ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged misleading statements and failure to disclose critical issues regarding the launch of its Inspire V product, leading to significant investor losses [2][7]. Allegation Details - The lawsuit claims that during the Class Period, Inspire Medical made false statements about the successful launch of Inspire V, while in reality, the launch faced poor demand and significant inventory issues [7]. - It is alleged that many medical centers did not complete necessary training and onboarding, which hindered the rollout of Inspire V [7]. - The company reportedly reduced its 2025 earnings guidance by over 80% following the revelation of these issues, resulting in a more than 32% decline in the stock price on August 4, 2025 [7]. Next Steps - Investors who purchased Inspire Medical shares during the specified period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].